Intensity Therapeutics Gross Profit

Intensity Therapeutics (INTS) currently reports a gross profit of $-20K as of March 2026. That compares with $-6K in the prior-year period — down 233.3% year over year. That is below the sector sector average of $600M. Use the charts on this page to explore Intensity Therapeutics's gross profit history and peer comparisons.

Intensity Therapeutics's gross profit decreased from $-6K to $-20K — a 233.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intensity Therapeutics's gross profit of $-20K is lower than the its sector sector average of $600M. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Intensity Therapeutics reported $-20K in gross profit as of March 2026. That compares with $-6K in the prior-year period — down 233.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-20K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $600M. From there, open related valuation or income-statement pages for Intensity Therapeutics, and consider following INTS for alerts when major investors trade the stock.